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This  is the second  of  two  reports  from  the  International  Workshops  on  Genotoxicity  Testing  (IWGT)
Working  Group  on Quantitative  Approaches  to Genetic  Toxicology  Risk  Assessment  (the  QWG).  The  ﬁrst
report summarized  the  discussions  and  recommendations  of the  QWG  related  to the  need  for  quantitative
dose–response  analysis  of genetic  toxicology  data,  the  existence  and  appropriate  evaluation  of thresh-
old  responses,  and  methods  to analyze  exposure-response  relationships  and  derive  points  of  departure
(PoDs)  from  which  acceptable  exposure  levels  could  be determined.  This  report  summarizes  the  QWG
discussions  and  recommendations  regarding  appropriate  approaches  to evaluate  exposure-related  risks
of  genotoxic  damage,  including  extrapolation  below  identiﬁed  PoDs  and  across  test  systems  and  species.
Recommendations  include  the selection  of  appropriate  genetic  endpoints  and  target  tissues,  uncertainty
factors  and  extrapolation  methods  to be considered,  the  importance  and  use  of information  on mode  of
action,  toxicokinetics,  metabolism,  and  exposure  biomarkers  when  using  quantitative  exposure-response
data  to determine  acceptable  exposure  levels  in human  populations  or  to  assess  the  risk  associated  with
known  or anticipated  exposures.  The  empirical  relationship  between  genetic  damage  (mutation  and  chro-
mosomal  aberration)  and  cancer  in  animal  models  was  also  examined.  It  was  concluded  that  there  is  a  gen-
eral correlation  between  cancer  induction  and  mutagenic  and/or  clastogenic  damage  for agents  thoughtPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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to  act  via  a genotoxic  mechanis
in  which  mutation  and  cancer  
of  the  same  species  and  strain
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m,  but that  the  correlation  is  limited  due  to an  inadequate  number  of  cases
can  be compared  at a sufﬁcient  number  of doses  in the  same  target  tissues
 exposed  under  directly  comparable  routes  and  experimental  protocols.
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. Introduction
A general framework for the assessment of the risk posed
y exposures to genotoxic agents has been deﬁned previously
y ﬁve working groups established by a joint program of the
nited Nations Environmental Program (UNEP) and the Interna-
ional Commission for Protection against Environmental Mutagens
nd Carcinogens (ICPEMC) [1]. The key elements of this framework
re (1) hazard assessment, (2) assessment of exposure to genotoxic
ubstances, (3) methods for dose and effect assessment, (4) risk
haracterization strategies for genotoxic environmental agents,
nd (5) monitoring environmental genotoxicants. The Working
roup on Quantitative Approaches to Genetic Toxicology Risk
ssessment (QWG), established by the International Workshops
n Genotoxicity Testing (IWGT), has extended those recommen-
ations based on discussions during 2012–2014 and at an IWGT
eeting in Foz do Iguac¸ u, Brazil October 31-November 2, 2013.
n a companion report of the IWGT QWG  [2] we have summarized
he discussions, consensus points, and recommendations regarding
ethods for the analysis of genotoxicity dose–response informa-
ion and for establishing points of departure (PoDs) from which
xposure-related risk can be estimated. This report summarizes
he QWG  discussions and recommendations related to extrapola-
ion from the PoD in order to establish acceptable human exposure
evels or to determine the exposure-related risk of genetic dam-
ge.
.1. Extrapolation below the PoD
Once a PoD for a relevant response in a test system and tissue or
ell type relevant to human health has been established, it is neces-
ary to select and apply appropriate extrapolation method(s) and
ncertainty factors (also referred to as safety factors or adjustment
actors, depending on regulatory application or context of use). The
hoice of appropriate methods and uncertainty factors depends on
nowledge of the mechanisms that determine the dose–response
elationship, and therefore information about the mode of action
s essential if uncertainty is to be minimized. For example, some
on-DNA-reactive mechanisms are expected to have a threshold
f exposure below which there is no biological effect (e.g. [3–7]).
hen evidence supporting the mechanism is sufﬁcient, a relatively
mall margin of exposure below a minimal effect level may  be
cceptable. On the other hand, DNA-reactive genotoxicants have
ften been considered to have a ﬁnite risk at any dose (e.g. [7,8]),
nd therefore, linear extrapolation below the PoD is often used.
hus, information on the mode of action of the agent under consid-
ration is an important determinant of the method of extrapolating
rom the PoD to an acceptable exposure level below the range of
easurable data. Examples of the types of mechanistic information
hat have been used by authoritative bodies to support the choice
f methodology are presented in Table 1.
While knowledge of mode of action can inform decisions on
ppropriate methods of extrapolation from the PoD to levels below
he measurable range of increases over background rates, the
ncertainty factors and level of conservatism applied are part of
he risk management decisions and depend on the nature of expo-
ure and the speciﬁc regulatory context that applies to the agent
nder consideration. Therefore these decisions are based primarily
n scientiﬁc information but are also impacted by legal and policy
onsiderations (e.g., see [21]).
.2. Extrapolation from in vivo dataPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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Because of the high relevance of in vivo animal data to human
isk estimation, and the difﬁculty of extrapolating directly from
n vitro cellular data to human risk, in vivo data are generally given PRESS
search xxx (2014) xxx–xxx
greater weight than in vitro results in the quantitative risk estima-
tion process. When performing a risk assessment, the most relevant
animal models (species, and target tissues) and genetic endpoints
must be selected to determine a suitable PoD (as discussed in the
previous report of the QWG  [2]). These choices should be based on
the adverse effects being evaluated, knowledge of the mechanism
of action, potential target tissues, and relevance of animal models
to the type(s) of human exposure anticipated.
Because effects vary among different tissues in a given ani-
mal  model, the selection of appropriate tissues for quantitative
dose–response analysis is critical. Also critical is the choice of end-
points to be used. The genotoxic endpoint selected for analysis
must reﬂect the information available from the hazard identiﬁca-
tion phase of the risk assessment, including the type of damage
determined to be characteristic of the agent under study (e.g., gene
mutations, DNA damage, chromosomal damage, etc.) and of the
expected health effect in humans. Further, this genetic endpoint
should be consistent with those that have been identiﬁed as key
events in an adverse outcome pathway leading from exposure to
disease [22–24]. The greatest weight should be given to those end-
points that are directly related to human diseases, such as gene
mutations, structural chromosomal aberrations, and aneuploidy
(see e.g. [25]). The appropriate endpoint should be determined in
the tissue that is the expected target site of action and/or those with
the highest expected exposure to the agent under consideration
and potential active metabolites. Gene mutations can be assessed
in virtually any tissue using transgenic animal models (e.g. [26–28]),
while cytogenetic analysis is currently limited to a few tissues in
which cells are actively dividing, or can be induced to divide, such
as bone marrow, circulating or splenic lymphocytes, or to some
extent liver (e.g. [29]). When appropriate, the micronucleus and
Pig-a assays in hematopoietic cells (bone marrow and/or blood) are
highly efﬁcient and relatively cost effective to assess chromosomal
damage and gene mutations, respectively.
Although hazard screening is generally carried out using a small
number of tissues in which assays are easily conducted, the choice
of a suitable tissue for quantitative analysis should be based on
available information on (1) site-speciﬁc toxicity, (2) mechanism of
toxicity and mechanistic expectations of important target tissues
(including carcinogenicity if information is available), (3) distribu-
tion and metabolism of the test agent in both the animal model
system and, if known, in humans, (4) exposure or accumulation
of the chemical and its relevant metabolites, (5) cell proliferation,
and potentially (6) the ability to repair the DNA damage induced by
the agent of interest. The interplay of these parameters will deter-
mine not only the target tissues and nature of the toxic and/or
genotoxic effects, but also the dose response relationships of the
key endpoints of concern, and therefore the determination of the
appropriate PoD within a relevant animal model. Other parameters,
such as the sensitivity or variability of the background frequency
of an endpoint and the number of animals and/or cells evaluated,
are also important to consider, especially in regard to the statistical
evaluation and sensitivity of the assays employed.
Other assays that measure DNA damage or cellular responses
to DNA damage and can be applied to multiple tissues are useful
but are given less weight than assays for mutations or chromoso-
mal  aberrations because such primary DNA lesions may be repaired
before conversion to inheritable DNA changes. Such assays and end-
points include DNA adducts [30], DNA strand breaks or alkali-labile
sites measured using techniques such as the comet assay [31], or
DNA repair or other damage-response assays (e.g. [32]). Assays that
use DNA strand breakage as the genotoxic endpoint also have thet on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
limitation that DNA strand breaks occur during DNA repair, cell
replication, apoptosis, and necrosis, and so strand breakage not
directly related to mutation or chromosomal aberration ﬁxation
may  occur.
ARTICLE IN PRESSG ModelMUTGEN-402548; No. of Pages 13
J.T. MacGregor et al. / Mutation Research xxx (2014) xxx–xxx 3
Table  1
Examples of mechanistic information used by authoritative bodies to infer that a non-linear threshold-type dose response occurred or that genotoxicity/carcinogenicity did
not  occur through a mutagenic or human-relevant mode of action.
Mechanistic information Example(s) References
Critical involvement of non-DNA targets Aneuploidy: benomyl; carbendazim [9–11]
Contribution of DNA repair mechanisms Ethylmethane sulfonate [9,12,13]
Detoxiﬁcation capacity exceeded Hydroquinone; paracetamol (acetaminophen) [9,14]
Disruption of enzymes involved in DNA synthesis or replication Topoisomerase II inhibitors; anti-metabolites; methotrexate [9,11]
Chemical reactivity or properties unlikely to occur in vivo Captan; trichloroacetic acid [14–16,18]
Inadequate uptake or toxicokinetics limiting distribution to target Chromium III [14,17]
Mutational spectrum in tumor genes similar to those in untreated animals Trichloroacetic acid [14]
Structural similarities to similar threshold-acting chemical Folpet; captan [14,18]
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Species and tumor-speciﬁc non-genotoxic mode of action 
In order to establish exposure limits that minimize human risk
f organ toxicity or carcinogenicity, PoD values from animal mod-
ls in conjunction with uncertainty factors are used (e.g. [33–38]).
he QWG  agreed that the same principles apply to analysis of
enotoxicity data. There are currently various approaches in use
or setting uncertainty factors when using animal data to assess
he risk of chemical toxicity and to determine a PDE (permitted
aily exposure), RfD (reference dose), TDI (tolerable daily intake),
r ADI (acceptable daily intake) (e.g. [34,38–44]). Often, a combina-
ion of default uncertainty factors (e.g., up to 10,000-fold or higher
djustments) is used to extrapolate to acceptable human exposure
evels when speciﬁc data are not available (e.g. [33,37,45,46]). These
efault approaches can be applied when there is no information
bout pharmacokinetics or actual exposure to the active form of
 chemical. Knowledge about exposure, metabolism, and pharma-
okinetics can help reﬁne the extrapolation to the human situation,
nd can often signiﬁcantly reduce the magnitude of uncertainty
actors that must be applied. In the case of the risk assessment
onducted after exposure of patients to EMS  as a result of contam-
nation of the HIV drug Viracept®, discussed in Appendix 2 [47],
etermination of the actual exposure in animals and pharmacoki-
etic modeling for humans using unlabeled and 14C-labeled EMS
llowed replacement of the critical uncertainty factors for expo-
ure with experimentally determined values, thereby considerably
owering the overall uncertainty of the risk determination.
The toxicokinetic properties, absorption, distribution,
etabolism, and excretion (ADME) of the agent under con-
ideration are critical factors in the risk assessment. Exposure
nformation can be obtained by direct analytical methods that
etermine levels of the agent under study and its important
etabolites in blood and tissues, or by measurement of cellular
eaction products such as DNA or protein adducts [48–50]. DNA
dducts are formed by reaction of a chemical with DNA [51,52] and
an thus be used as a surrogate marker of a biologically effective
ose. The stability of a DNA adduct and its consequent conversion
nto a stable mutation is determined by the cell’s DNA repair
apacity and the turnover rate of the damaged target cells. The
isk of conversion into permanent genetic damage before repair is
ompleted is dependent on many factors, including the nature of
he adduct and its position in the DNA as well as the number of
nduced adducts in a speciﬁc tissue and speciﬁc factors such as cel-
ular replication rate [48]. Thus, the likelihood that an adduct will
e converted to a mutation depends on the type of DNA adduct, its
ffect on base pairing, and the efﬁciency and ﬁdelity of DNA repair
n a particular tissue or cell type. The characteristics of the DNA
dducts and of repair processes often also provide insights into
he mechanism of cellular pathology. It is important to note thatPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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arious types of DNA repair are error-prone, and so not only the
otential ﬁxation of a mutation via misreading the adducted base
ut also the potential for errors arising from removal of the adduct
r by translesion synthesis may  be determinants of the mutationaldative damage; ethylene glycol monobutyl ether [14,19]
ction of thyroid follicular cell tumors by inorganic chlorates [20]
risk [53]. Thus, adduct data can be used to quantify exposures, can
contribute to elucidating the biological mechanism of mutagenic
and clastogenic events, and/or can be used to quantitatively
evaluate dose response relationships.
Methods and analytical tools for adduct identiﬁcation and/or
quantitation have been summarized and reviewed (e.g., [49,54,55]).
Such data can be used to identify speciﬁc adduct patterns induced
by exogenous chemicals and thus contribute to elucidating the bio-
logical mechanism and/or used to quantitatively evaluate the dose
response relationship. Due to the active removal of DNA adducts
by repair mechanisms, a quantitative evaluation needs to take into
account the kinetics of these processes. When using DNA adducts
to support quantitative risk assessment, it is of course necessary to
take into account the level of DNA adducts formed endogenously by
normal cellular metabolism, oxidative stress, and daily background
exposures [56], as well as the chemical’s toxicokinetic proper-
ties, including absorption, distribution, metabolism, and excretion
(ADME) [48–50,56].
Hemoglobin adducts can also serve as sensitive surrogate mark-
ers of “internal” exposure to a chemical [57,58]. In contrast to
DNA adducts, hemoglobin adducts are not actively removed from
the protein, and therefore their half life depends only on the ery-
throcyte lifespan if the adduct is chemically stable. For a direct
extrapolation from animals to humans based on exposure data
from hemoglobin adducts, the species speciﬁc lifespan of erythro-
cytes needs to be taken into consideration (approximately 41, 61
and 122 days in mice, rats and humans respectively [59–61]).
The relatively well characterized and long lifespan of the ery-
throcyte make hemoglobin adducts a sensitive and quantitative
indicator of exposure and allows estimation of the area under the
(concentration–time) curve (AUC) values determined in toxicoki-
netic studies [62]. Mechanism-based models using hemoglobin
adducts as a measure of AUC have been proposed for cancer risk
assessment of genotoxic chemicals [63,64]. However, hemoglobin
adducts cannot be used to directly address exposure levels in target
tissues or organs other than blood. DNA adducts can be measured
directly in the relevant target tissues of concern, but are less use-
ful for AUC calculations as their rates of repair vary and it is more
difﬁcult to obtain repeated measures of tissues that can only be
accessed invasively. Information from animal experiments on the
proportionalities between formation of DNA adducts in different
organs and of hemoglobin in blood can be useful for extrapola-
tion to internal tissue dose (or AUC) in different organs when such
information is known for a given chemical or class of chemicals.
To illustrate how the considerations discussed above can be
addressed experimentally and the results interpreted quantita-
tively in the context of the risk assessment framework presented,t on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
we summarize in Appendix 2 the risk assessment conducted when
a large number of patients were exposed to an ethyl methanesul-
fonate (EMS) contaminant in the drug Viracept®, administered for
treatment of human immunodeﬁciency virus (HIV) infection. Due
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Fig. 1. A plot of BMD10 for cancer induction vs.  BMD5 for micronucleus induction calculated from 26 cases in which both rodent cancer and micronucleus induction data
were  available for the same agent. For each chemical the point of crossing indicates the point estimates of the BMD. The corresponding crossing lines indicate the BMDL  (low
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and  of line) and the BMDU (high end of line). Thus the total length indicates the stat
t  which the carcinogenic BMD10 values are 10-fold higher than the micronucleus
olid  line. Modiﬁed from [66], with permission.
o the highly signiﬁcant exposure to this DNA-reactive mutagen,
t was necessary to determine the risk of genetic damage in the
xposed individuals and to determine whether appropriate follow-
p health care and possible long-term monitoring for carcinogenic
utcome via a cancer registry was necessary. The approach taken
epresents a case of a quantitative risk analysis in which good
xperimental genotoxicity data combined with mechanistic and
xposure information allowed the conclusion of negligible risk at a
alculated margin below the derived PoDs in the absence of sufﬁ-
ient carcinogenicity data. The exposed individuals had exposures
ower than the derived negligible risk levels, and the responsible
egulatory authority concurred that the analysis demonstrated a
egligible risk for the exposed population. This example reinforces
ur conclusion that good exposure and PK information combined
ith a mechanistic understanding of cellular protective mecha-
isms allows uncertainty factors to be minimized and can lead to
greement by regulatory authorities on acceptable exposure levels.
.3. Quantitative correlations between cancer potency, early
ancer-related genetic endpoints, and preneoplasia
Given the importance of predicting carcinogenic risk and the
nown association of genetic damage with cancer induction, the
WG  also considered quantitative correlations between carcino-
enic and mutagenic potency for chemicals for which there is
echanistic information suggesting that mutagenicity (or clasto-
enicity) is a key event on the pathway to carcinogenesis. The
bjective was to determine the extent to which quantitative geno-
oxicity data, particularly mutagenicity and clastogenicity data,
ould be used to predict carcinogenic outcomes and potency and
o reﬁne cancer risk assessments. The QWG  considered two types
f correlation: (1) correlation of in vivo mutagenic and clastogenic
otency with carcinogenic potency without restriction to identi-
al species, strain, sex, or tissue target sites, and (2) correlationPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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f in vivo mutagenic and clastogenic potency with carcinogenic
otency within a given target tissue in the same species, strain,
nd sex of laboratory animal exposed by the same route. uncertainty in the BMD  value. The solid diagonal line indicates the point estimates
values. The upper and lower dashed lines represent 10-fold above and below the
1.4. Correlation of in vivo mutagenic and clastogenic response
with carcinogenic potency without restriction to identical species,
strain, sex, or tissue target sites
The quantitative relationship between gene mutation in trans-
genic rodent models and micronucleus induction (an index of
chromosomal aberrations) in bone marrow (or peripheral blood
erythrocytes) with carcinogenic potency has been examined by
Hernandez et al. [65,66], using quantitative dose–response anal-
ysis of the genotoxicity data. Although these data were, in general,
not tissue or strain matched, a remarkably good quantitative cor-
relation with carcinogenic potency was observed.
The comparison of BMDL values calculated using data from
micronucleus and transgenic rodent studies vs. the carcinogenic
BMDL10 was examined for 18 compounds [65]. The correlation of
carcinogenic with mutagenic/clastogenic potency over ﬁve orders
of magnitude showed a high degree of correlation on a log-log scale
even though genotoxicity data were in most cases from tissues
other than the cancer target site (i.e., genotoxicity data were from
the tissue in which the tumor arose for only 4 of the compounds
used in this analysis, and the route of exposure was  different for half
of the compounds). In another study, analysis of 26 compounds for
which micronucleus and carcinogenic BMDs could be calculated
also showed a strong correlation between carcinogenic and geno-
toxic potencies as estimated by the reciprocal of the BMD [66].
These data from the latter study, shown in Fig. 1, illustrate both the
general overall correlation observed and also the factors that limit
such comparisons when tissue target site, species, strain, sex, route
of administration and other experimental variables differ among
the studies being compared.
Fig. 1 shows a clear correlation between the cancer and the
micronucleus BMDs, even though the species, strain, sex, dosage
route, and tissue target sites for cancer and micronucleus induc-
tion were not matched. Given that metabolic activation and tumor
induction generally occur in tissues other than bone marrow (thet on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
target tissue in the micronucleus assay), and that tumor potency
often differs signiﬁcantly among different tissues and different
species/stains of animal, this is a remarkably good correlation and
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uggests that tissue-matched data should give an excellent corre-
ation. The BMDL5 for the genetic toxicity endpoint was  lower than
he tumor BMDL10 in 23/26 (88%) cases. Of course this percentage
ill be different for different methods for calculating the BMD  and
ifferent sizes of BMR  (See [66] for the method used to generate
ig. 1). Nevertheless the correlation should remain, regardless of
ow the BMD  is deﬁned or calculated. There were only three com-
ounds for which the tumor BMDL10 was lower than the BMDL5
or micronucleus induction (Fig. 1). For tetrachloroethylene (TCE),
he upper limit of the micronucleus BMD5 (the BMDU5) is inﬁnite,
hich is consistent with the micronucleus data not showing a sta-
istically signiﬁcant dose response. N-nitrosodimethylamine (NDA)
s genotoxic but is activated to a short-lived reactive intermediate in
iver, the site of carcinogenesis, and therefore genotoxicity in bone
arrow would not be expected to predict quantitative responses
n liver. 1,2-dimethylhydrazine (DMH) is a colon carcinogen that
s metabolized in the liver to a conjugate with glucuronic acid.
his glucuronide enters the gut both with bile and directly via the
irculation, and microbial beta-glucuronidase releases the active
etabolite which, in turn, alkylates tissue macromolecules [67].
his mechanism of carcinogenic action of DMH  in rat colon is not
xpected to occur in bone marrow.
Thus, considering both the Hernandez et al., 2011 and 2012
eports [65,66], there is a general quantitative correlation between
arcinogenic and mutagenic or clastogenic potency for a wide range
f agents believed to have a genotoxic mode of cancer induction,
ut metabolic, toxicokinetic, and distributional properties limit
he precision of these potency correlations when comparisons are
ade between studies that differ in tissue target site, species,
train, sex, dosage route, etc., unless these factors are taken into
ccount. Nonetheless, these results suggest that, in the absence of
arcinogenicity data, an estimate of probable cancer potency can
e derived from in vivo genotoxicity studies.
.5. Correlation of mutagenic and clastogenic response with
arcinogenic outcome in the same target tissue, species, strain,
nd sex of animal when exposed by the same route
Consideration of the dose–response characteristics of muta-
enic and clastogenic responses in the cancer target site
organ/tissue of the species and strain under study) was undertaken
o determine if such data could be useful in reﬁning carcinogenesis
isk estimates in those cases in which mutagenesis or clastogenesis
re key events in the pathway to carcinogenesis. Because the deter-
ination of cancer incidence is always limited by the statistical
ncertainty associated with a stochastic response in a small num-
er of animals, it was hoped that mutation data and concurrent
ata on pre-neoplastic lesions, such as glutathione S-transferase
GST)-positive foci in liver, which can readily be determined in
 cost-effective manner, could be used to improve the estimates
btained.
A survey of available data on genotoxicity outcomes for chem-
cals that have undergone cancer bioassays, taking into account
hat assays with OECD test guidelines are preferred because stan-
ardized protocols greatly facilitate comparisons, found that the
tandardized in vivo genotoxicity assay for which data was most
ften available was the rodent erythrocyte micronucleus assay.
owever, this assay only provides information about two  types
f genotoxic damage (structural chromosomal damage and ane-
ploidy) in the hematopoietic cells of the erythrocytic lineage.
stablishment of an OECD guideline for the transgenic rodent muta-
ion assays has resulted in increasing amounts of data on genePlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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utations using standardized protocols, but the number of cases
n which mutagenicity data were available at a sufﬁcient number
f doses in the organ/tissue target site of carcinogenesis, and in
he same species and strain in both assays, was extremely limited. PRESS
search xxx (2014) xxx–xxx 5
Likewise, we found only a very limited number of cases in which
data on pre-neoplastic lesions were available along with compa-
rable cancer and genotoxicity data in comparable species, strains,
tissues, and exposure regimens. In those few cases in which we
did identify matched carcinogenicity and genotoxicity data, there
were generally not a sufﬁcient number of doses to obtain quanti-
tative dose–response metrics. Thus, we  were unable to identify a
sufﬁcient number of data sets to assess the quantitative correlation
between carcinogenic potency and mutagenesis and clastogenesis
within the same target tissue, species, strain, and sex. The dearth
of such information was  unexpected, and constitutes a very sig-
niﬁcant need in the ﬁeld of genetic toxicology and cancer risk
assessment.
In Appendix 1 we present a case example that illustrates the type
of quantitative analyses and comparisons that we had hoped could
be conducted for a range of structurally dissimilar chemicals. This
example is that of the carcinogenic and genotoxic responses in the
liver of F344 rats exposed to 2-amino-3,8-dimethylimidazo[4,5-
f]quinoxaline (MeIQx) under comparable study conditions. This
is the agent for which we  identiﬁed the most comprehensive
set of genotoxicity and carcinogenicity data under compara-
ble study conditions. In this case, as shown in Fig. 2, early
genotoxic events in the pathway to carcinogenesis showed the
expected trend of lower PoDs for earlier events in the pathway
to disease (DNA adducts4weeks  Mutations 16weeks < GST-positive
Foci16–32weeks  Cancer56weeks). However, the QWG  was unable to
identify a sufﬁcient number of additional cases with sufﬁcient data
to determine if generalizations could be made. We  strongly recom-
mend that additional data of this type should be generated for cases
in which genotoxicity is a key step in the carcinogenesis process so
that these important relationships can be studied.
2. The role of in vitro data
2.1. Mammalian cells
Genotoxicity data from in vitro mammalian cell assays are used
routinely for hazard identiﬁcation, mechanistic studies, and as sup-
porting information in the quantitative risk assessment process.
The QWG  also discussed the feasibility of estimating quantitative
in vivo risk by extrapolating from in vitro data. The 2007 National
Research Council Report “Toxicity Testing in the 21st Century: A
vision and a strategy” [68,69] recommends development of an
integrated, toxicity pathway-oriented approach based on compu-
tational systems biology pathway modeling using in vitro cells in
combination with reverse dosimetry models to derive acceptable
in vivo exposure limits. Such approaches are still in an early stage of
development and their utility for routine quantitative assessment
of hazard and risk remains unclear. One example of an attempt
to use such an approach for the analysis of genetic effects is the
recent report of Li et al. [70] that describes dose–response modeling
of the effects of etoposide on DNA damage and damage-response
pathways. To build such models, however, requires extensive data
on free concentrations in solution, protein binding, etc. Other
limitations of using mathematical models of toxicity pathway per-
turbations for estimating small increases in risks, a major focus of
the National Academy document, have been discussed by Crump
et al. [71,72].
Various approaches for physiologically based pharmacokinetic
(PBPK) modeling to conduct quantitative in vitro to in vivo
extrapolation are currently being investigated [73,74]. Many oft on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
these currently focus on speciﬁc endpoints such as prediction of
metabolism or clearance. Much effort is still needed to improve
these approaches before they become routine tools to improve
quantitative in vitro to in vivo extrapolation for genotoxicity. In
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Fig. 2. Dose–response plots and derived BMD values for DNA adducts, mutations,
iver  by exposure to MeIQx.
rder to draw a ﬁnal conclusion, data on the intracellular expo-
ure of chemicals would likely be required to build and apply the
odels, but such data are rare. Therefore risk assessment based on
n vitro mammalian cell data should probably be limited to situa-
ions with a relatively low risk as identiﬁed by hazard screening and
xposure assessments, in which in vivo metabolism is well charac-
erized and can be properly modeled, and/or by using additional
ncertainty factors if extrapolation is made from the BMDLs of in
itro experiments to acceptable human exposure.
In general, uncertainty factors would be expected to be related
o the degree of relevance of the experimental model to humans,
nd uncertainty factors would be included resulting in a cumulative
actor by which the margin of exposure would be divided. This rela-
ionship and the relationship of exposure information in different
odels are illustrated in Fig. 3.
Although there are clearly uncertainties when quantitatively
xtrapolating in vitro data to estimate human in vivo risk, in vitroPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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tudies can be useful when knowledge of mechanism, metabolism,
nd exposure permits quantitative extrapolation or comparison.
or example, in vitro data may  allow the estimation of the in vivo
Fig. 3. Uncertainty related to estimation of human risk.ositive foci, and liver hepatocellular adenoma and carcinoma induced in F344 rat
concentration of an unbound direct-acting DNA-reactive agent that
would be expected to elicit a deﬁned BMR  (e.g., obtained by extrap-
olating data from a PoD to the benchmark concentration (BMC) at
the desired BMR), and in the absence of in vivo genotoxicity data
this may  permit estimation of an acceptable in vivo dose associated
with minimal risk of genotoxic damage (provided that in vivo data
that relates dose to blood and/or tissue concentrations is available).
Another use would be to use a deﬁned BMD  or BMC  to rank poten-
cies of related compounds in a series. And importantly, as increased
knowledge and experience with regard to analysis of responses
in adverse outcome pathways and in vitro measurement and pre-
diction of exposure to chemical species responsible for pathway
perturbations continue to accumulate, it is expected that the util-
ity of these approaches for quantitative predications will continue
to increase.
2.2. Bacterial mutagenicity assays
The question of whether or not a quantitative relationship exists
between mutagenic potency in the Salmonella (SAL) based Ames
test [75,76] and carcinogenic potency was a matter of scientiﬁc
debate in the late 1970s. Early reports showed a high qualitative
positive predictivity (>90%) of SAL results for rodent carcinogenic-
ity [76,77] but did not address whether there was a quantitative
correlation with carcinogenic potency. When a larger number
of chemicals with diverse modes of action had been evaluated,
even the qualitative correlation between SAL and carcinogenic
potency in rats was found to be much lower than originally
thought [78–82]. From a quantitative perspective, Meselson and
Russel [83] for example, initially found a nearly perfect linear
relationship between carcinogenic potency in rodents and muta-
genic potency in Salmonella for 10 of the 14 chemicals studied,
but this quantitative predictivity was  considerably lower whent on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
a broader set of chemical classes was investigated [84–86]. The
QWG recognizes that bacterial mutagenicity assays are useful for
the evaluation of reactive potential and ability to interact with
DNA, that many documented human carcinogens are positive in
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he Ames assay, and that they are therefore important compo-
ents of hazard evaluation and mechanistic studies. However, the
WG  noted that while bacterial assays can be useful for rank order-
ng the mutagenic potency within structurally similar compounds,
acterial physiology and anatomy is too different from mammals
nd humans to support their use for quantitative extrapolation to
uman risk.
.3. Metabolic activation in in vitro studies
One factor that limits quantitative extrapolation from in vitro
ystems to in vivo effects is the fact that adverse interactions of
any mutagenic agents with genetic material only occurs fol-
owing in vivo metabolic conversion into reactive metabolites.
arly studies showed that in vivo mammalian metabolic conver-
ion of mutagenic carcinogens such as dimethylnitrosamine and
-acetylaminoﬂuorene to highly reactive electrophiles is respon-
ible for their ability to readily attack DNA (e.g. [87]. It was
hen shown that other classes of mutagenic compounds, includ-
ng nitrosamines, PAHs, and aromatic amines, are converted to
eactive metabolites via oxidative hepatic metabolism. In the
arly 1970s, Malling ﬁrst suggested using rodent hepatic prepa-
ations in in vitro bacterial mutagenicity assays to simulate
ammalian hepatic metabolism [88]. The use of an exogenous
ource of metabolic enzymes such as the post-mitochondrial super-
atant (PMS) of homogenized rat livers (i.e., referred to as rat
iver S9 when the 9000 × g supernatant fraction is employed)
rom rats previously treated with Ah-receptor agonists such as
roclor-1254 to increase metabolic activity was then shown
o enable demonstration of in vitro mutagenic activity for a
ide variety of chemical carcinogens [76,89]. Hepatic prepa-
ations from other species or strains of animals (e.g., B6C3F1
ouse, F344 rat, Golden Syrian Hamster) and/or alternative tis-
ues or inducers (e.g., phenobarbital/5,6-benzoﬂavone, ethanol)
re now commercially available and are frequently used ([90];
ww.moltox.com). A NADPH generating system based on glucose-
-phosphate dehydrogenase, and assay concentrations of hepatic
9 ranging from 1 to 10% v/v (typically 1–2% v/v) are most com-
only used. However, although mutagenic activity of many
hemical carcinogens can be demonstrated in in vitro systems,
uantitative extrapolation to in vivo carcinogenic potency remains
roblematic due to the complexity of the metabolic pathways
nvolved.
The utility of human hepatic preparations for the in vitro acti-
ation of mutagens has been evaluated, and differences in the
ctivity of oxidative hepatic enzymes (e.g., P450 1A1) between
uman preparations and those routinely employed for in vitro
enotoxicity assessment have been noted (i.e., Aroclor induced
at liver).1 Analyses of enzymatic activity data from commer-
ial preparations indicate that average human hepatic levels of
ROD and MROD activity (i.e., P450 1A1 and 1A2) are approxi-
ately 100 pmols min−1 mg  protein−1 and average levels of BROD
ctivity are approximately 45 pmols min−1 mg  protein−1 (P450 2B1
nd 3A), and that the distribution of P450 isozyme activity
n humans is highly positively skewed. Some pooled prepa-
ations showed EROD, MROD and BROD activities as high as
86, 526 and 296 pmols min−1 mg  protein. In comparison, aver-
ge EROD and MROD activity levels in hepatic preparationsPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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rom uninduced Sprague-Dawley rats are approximately 55 and
5 pmols min−1 mg  protein−1, respectively, with average BROD
evels approximately 75 pmols min−1 mg  protein−1. Thus, human
1 Personal Communication, manuscript in preparation: J.A.Cox, M.Fellows,
.Hashisume, P.A.White. Utility of Human Hepatic S9 for Routine Regulatory Evalu-
tion of Genetic Toxicity. PRESS
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hepatic capacity of some P450-mediated oxidation reactions is
similar to that expected for uninduced Sprague-Dawley rat; how-
ever, Aroclor induction results in increases in EROD and MROD of
100-fold or more, and approximately 30-fold increases in BROD
and PROD activity levels (i.e., 2B1, 3B2 and 3A). Thus, the use of
induced rat liver S9 adds an element of conservatism because of the
large increases in activities that are induced. Induction with other
Ah-receptor agonists (e.g., phenobarbital/5,6-benzoﬂavone) show
similar increases in the activity of hepatic P450 isozymes, and rel-
ative differences in the capacity for in vitro oxidative metabolism
between humans and rodents. However, such differences among
different inducers add to the complexity of effectively using in vitro
genetic toxicity assessment data for quantitative evaluation of
human risk.
Although exogenous metabolic activation mixtures containing
the popular Aroclor-induced rat liver S9 (or similar) have proved
to be highly effective for the detection of bacterial mutagens, a
number of factors hamper effective use of S9-containing activation
systems for in vitro genotoxicity assessment in mammalian cells.
One important factor is that exogenous metabolic activation mix-
tures containing hepatic S9 have been shown to be highly toxic for
mammalian cells (e.g., CHO, TK6, V79, L5178Y, etc.) that are rou-
tinely employed for genotoxicity testing [91]. Other factors include
inadequate knowledge regarding the endogenous metabolic capac-
ity of the cells, the properties of the compound, the optimal level
of exogenous metabolic activation, and binding of the test article
to S9 proteins.
It is important to note that in vivo metabolism involves a
complete complement of Phase I and II enzymes for oxidation,
reduction, hydrolysis and conjugation, while in vitro activation
systems contain a restricted subset of Phase I and II enzymes in
an activation mixture that, for the most part, contains cofactors
that preferentially facilitate cytochrome P450-mediated oxidative
reactions. Although the above discussion has focused on in vitro
simulation of oxidative metabolism for the generation of mutagenic
metabolites, many mutagens require other types of enzymatic
reactions. For example, diazo compounds and nitroarenes require
reductive metabolism to generate arylamine intermediates that
can subsequently be converted to hydroxyarylamines via P450 1A2
[92–95]. Potent mutagens can be generated by reductive cleav-
age of benzidine-based diazo compounds, and metabolic activation
mixtures containing FMN  (ﬂavin mononucleotide) and hepatic S9
from Golden Syrian Hamsters have been employed to improve
detection of this class of mutagens [92]. Moreover, enzymes that
facilitate conjugation reactions (e.g., sulfotransferase, glutathione-
S-transferase, or acetylase) play an important role in the activation
of some mutagens and this can also be simulated in vitro, although
this is not commonly done. Examples include exogenous activation
mixtures or transgenic expression systems for the generation of
mutagenic metabolites of halomethanes and N-hydroxyarylamines
[96–98]. These additional enzymatic requirements further com-
plicate the use of in vitro mutagenicity data for quantitative
assessments of agents that require metabolic activation for activ-
ity.
3. Conclusions and recommendations
3.1. General
• The QWG  supports the use of in vivo genotoxicity dose–response
data to determine PoDs to be used, with appropriate extrapo-t on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
lation methods and uncertainty factors, to establish regulatory
exposure limits, and, in conjunction with human exposure
data, to assess and manage the risk of adverse health
effects.
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.2. Recommended endpoints for quantitative human risk
ssessment
Among types of genotoxicity endpoints, those associated with
human disease should be given the most weight when con-
ducting a human risk assessment. These include mutagenicity,
clastogenicity, and aneugenicity. Those selected should also be
consistent with those that have been identiﬁed as key events in
an adverse outcome pathway leading from exposure to disease.
DNA damage assays, such as DNA strand breaks as determined
by the comet assay, measurement of DNA adducts, and cellular
DNA damage responses can be useful to determine the DNA reac-
tivity of a chemical or the presence of DNA damage, and can be
used to demonstrate an absence of strand breakage and there-
fore reduced potential to induce heritable alterations. However,
their utility for quantitative evaluations is limited because the
extent to which DNA damage may  be repaired before conversion
to a permanent genetic alteration is difﬁcult to ascertain. Sta-
ble DNA adducts may  have a greater potential for conversion to
mutations, especially when of a type known to cause base pair-
ing errors. DNA strand breaks occur during DNA repair and during
apoptosis and necrosis, and so strand breakage may  not always
be related directly to the formation of mutations or chromosomal
aberrations.
.3. Recommended test systems, target tissues, and exposure data
or human risk assessment
The tissues chosen to be used in support of risk assessment should
be those most likely to be exposed to the highest level of the reac-
tive form of the toxicant under study and/or be a suspected site
of biological action. Selection can be based on available informa-
tion on (1) toxicity, (2) exposure or accumulation of a chemical,
including route of exposure, (3) cell proliferation, (4) metabolism,
(5) knowledge of mechanism of action, and potentially (6) DNA
repair capacity or even (7) information about carcinogenicity.
Parameters and uncertainty factors to be considered when
assessing risk or setting exposure limits include (a) species dif-
ferences and allometric scaling, (b) differences in absorption,
distribution, metabolism and pharmacokinetics, (c) differences
in duration of exposure, (d) severity of toxicity endpoint, (e) vari-
ability among individuals, (f) uncertainty in PoD or NOEL. When
data that permit assessment of these parameters/factors are not
available, uncertainty factors should be applied to the predicted
acceptable exposure level to account for the absence of data.
When the actual exposure and pharmacokinetic/metabolism
characteristics of the agent under consideration have been deter-
mined, uncertainty factors can be replaced with experimentally-
determined parameters that may  justify higher allowable
exposures.
In addition to analytical determination of plasma and tissue expo-
sures, DNA or hemoglobin adducts are useful metrics of exposure,
and DNA adducts are also useful for determination of the mode
of genotoxic action.
.4. Use of mode of action information in quantitative risk
ssessment
Mode of action information is very important, and can help
select relevant endpoints for study and appropriate extrapolation
methods. It can also help identify potential species differencesPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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in critical physiological/biological factors that modify risk and
impact uncertainty factors, and can determine whether more or
less conservative extrapolation methods and uncertainty factors
should be applied in the risk assessment. PRESS
search xxx (2014) xxx–xxx
• The decision whether a linear or non-linear approach should be
used to estimate low dose risks should be based on a mode of
action understanding. When adequate MoA  information is not
available, risk management or policy decisions may need to be
made based on default assumptions or regulatory policy require-
ments.
• The entire weight of the evidence, within the broader context of
the toxicity, pharmacodynamics, ADME, and toxicokinetics of the
chemical, should be considered.
• Carcinogenic potency of agents believed to involve mutation
or chromosomal aberration as key events in the carcinogenic
process shows a general correlation with the potency of gene
mutation induction in vivo and micronucleus induction in
hematopoietic tissue, even when the data are from different tis-
sues, experimental protocols, and species/sex/strain of animal.
It is expected that the strength of this correlation would be
improved if mutation and chromosomal aberration data were
available from cancer target tissues in the same strain, species,
and sex of animals exposed by the same routes using similar
protocols, but sufﬁcient data to obtain the quantitative metrics
necessary to examine this assumption were not found by the
QWG. The QWG  recommends that such data should be generated.
• In the case of MeIQx, a genotoxic carcinogen for which
good data on the induction of DNA adducts, mutations,
GST-positive foci, and tumors in the liver of F344 rats
are available, an analysis of the dose–response relation-
ships showed that the quantitative order of induction of
these events was: DNA adducts4weeks  Mutations16weeks < GST-
positive Foci16–32weeks  Cancer56weeks.
3.5. Use of in vitro data in quantitative human risk assessment
• In vitro mammalian cell data may  be useful in quantitative
risk assessment if exposure to the active form of the agent is
known. Differences in bacterial permeability, DNA repair, and
metabolism as compared to mammalian cells make quantitative
extrapolation from bacteria very difﬁcult, other than for potency
ranking within structural classes. Mammalian cell data may  also
be used for potency ranking among related agents with similar
modes of action.
• Factors of uncertainty are expected to increase with the extent of
phylogenetic differences between the experimental model and
humans and with the relevance of the test system to human expo-
sure, pharmacokinetics, and metabolism. Identiﬁed uncertainty
factors would be combined and result in the use of a cumulative
factor to determine the margin of exposure.
Addendum
After completion of this manuscript, three important publica-
tions from the Health and Environmental Sciences Institute project
on Risk Assessment in the 21st Century (RISK21 Project) have
appeared [99–101]. These publications are highly relevant, and are
complementary to the two  reports of the IWGT Working Group
on Quantitative Approaches to Genetic Toxicology Risk Assess-
ment. We call attention particularly to the discussion of the “key
events/dose response framework” (KEDRF) presented in the Simon
et al. [101] publication.
Conﬂicts of interestt on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
J.T.M. consults for regulated industries, government agencies,
and laboratories that develop and/or perform regulatory genetic
toxicology tests. No other conﬂicts of interest were noted.
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ppendix 1. Analysis of the relationships among PoDs for
arcinogenic and genotoxic effects associated with MeIQx
xposure
Because cancer has been shown to be a multistep process that
onsists of a series of progressive key genetic, epigenetic, and cel-
ular events that lead to uncontrolled cell proliferation [102,103],
nd because only a minority of early events progress to cancer, it
s expected that the measurement of key events that occur ear-
ier in this process would occur at a higher frequency and be more
ensitive than later events (i.e., would have lower BMD  values).
One example for which good data were available is the data
howing the response of key events in the liver of F344 rats
xposed to the model genotoxic hepatocarcinogen 2-amino-3,8-Please cite this article in press as: J.T. MacGregor, et al., IWGT repor
Use of point-of-departure (PoD) metrics in deﬁning acceptable expos
Environ. Mutagen. (2014), http://dx.doi.org/10.1016/j.mrgentox.2014
imethylimidazo[4,5-f]quinoxaline (MeIQx)[104]. Rats exposed to
his carcinogen were examined to determine the formation of 1)
eIQx-DNA adducts [105], 2) mutations at the H-ras locus [106]
nd in LacI transgenes [107], 3) pre-neoplastic lesions (PNL) in the PRESS
search xxx (2014) xxx–xxx 9
form of GST-positive foci [105], and 4) hepatocellular adenomas
and carcinomas [108]. These endpoints were evaluated at 4, 16,
16–32 and 56 weeks of repeat dosing, respectively. In preparation
for the IWGT 2013 workshop the BMD  and BMDL were calculated
using PROAST modeling software [109] to provide standardized
metrics for each parameter for comparison. It was shown that the
BMD10 and BMDL10 ranking along the path of carcinogenesis was
as expected; i.e.,  earlier key events increased at earlier times and
at lower doses than those closer to the apical endpoint of cancer
induction (Fig. 2). The quantitative order of signiﬁcant induc-
tion of the events measured was: DNA adducts4weeks  Mutations
16weeks < GST-positive Foci 16–32weeks  Cancer56weeks.
It should be noted that the BMD10 for cancer induction and
the BMD10 for the genotoxicity endpoints are not equivalent met-
rics. The BMD10 for cancer induction is based on an absolute 10%
increase in the incidence of tumor-bearing animals whereas the
BMD10 for genotoxicity induction is based on an increase equal to
10% of the spontaneous damage rate in the group of animals exam-
ined (see [2]). Thus, the selected metrics for genotoxicity damage
are inherently much more conservative, in that they reﬂect the sen-
sitivity of the genotoxicity assays to detect much smaller increases
relative to the existing background rate than does the cancer bioas-
say.
Because tumor sequencing studies suggest that over time the
cells which become tumor cells may  accumulate multiple “driver”
mutations among an even larger number of “passenger” mutations
that do not confer selective growth advantage [110], a mutation can
be one of several “key” (i.e.  necessary) events in tumor induction
and so knowledge of the rate-limiting key steps in mutagenesis and
carcinogenesis is important when attempting quantitative predic-
tions. Correlative data such as that above is necessary to achieve
this understanding.
It is unfortunate that other examples with similar extensive data
sets could not be identiﬁed by the QWG, and it is recommended
that such comparable data should be developed for other carcino-
genic agents to allow further evaluation of the extent to which
quantitative predictions about cancer outcome can be made based
on quantitative analysis of mutagenic events in the carcinogenesis
process. Because studies from different laboratories are often con-
ducted for different purposes, when attempting to combine studies
from different literature reports involving the endpoints from a
pathway of interest, it is rare that studies of a compound conducted
by different labs all use the same experimental conditions and route
of exposure, species, strain, sex, and target tissue of the animals
under study. Thus, we  suggest that it may  be necessary to prospec-
tively undertake studies designed to investigate the sensitivity of
key genetic events relative to cancer outcome in order to provide
the information necessary to bring such analyses into practical reg-
ulatory use. Options for obtaining such data could be the inclusion
of genetic measurements in animals already undergoing carcino-
genesis studies or in satellite groups of animals with appropriate
transgenic markers.
Appendix 2. EMS/Viracept® case study: example of a
successful quantitative risk assessment
The need for a quantitative risk assessment of human exposure
to ethyl methanesulfonate (EMS) was triggered by an accidental
exposure of patients to EMS  after ingesting contaminated Viracept®
(Nelﬁnavir mesylate) tablets. In early 2007, it was discovered that
the impurity had formed over a period of time in a storage tankt on quantitative approaches to genotoxicity risk assessment II.
ure limits and assessing human risk, Mutat. Res.: Genet. Toxicol.
.10.008
for methanesulfonic acid after the cleaning ﬂuid (ethanol) was not
properly removed prior to reﬁlling. The contaminant remained dur-
ing the synthesis process and was  found in the ﬁnished product
at levels reaching approximately 1000 ppm. Retrospective analysis
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Table 2
Analysis of NOEL and breakpoint dose for EMS  [111,112].
Study Organ NOEL (mg/kg) Breakpoint dose (BPD) (mg/kg) 95% Conﬁdence interval of BPD (mg/kg)
89.8
35.4
s
E
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i
d
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m
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e
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e
t
b
m
t
l
b
d
i
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L
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i
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a
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g
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t
c
t
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a
i
a
c
b
a
e
a
i
p
a
a
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a
a
l
t
tMNT  Bone marrow 80 
MutaTMmouse Bone marrow 25 
howed that tablets produced prior to the incident had contained
MS at levels several orders of magnitude lower, verifying that
iracept® manufactured during a three month period was contam-
nated. However, a signiﬁcant number of patients were exposed
uring this period. Details on this case and how it was managed
an be found in the Special Issue No. 190 of Toxicology Letters [47].
In the course of the animal studies on the genotoxic activity of
MS, the clastogenic effects were investigated in bone marrow of
ice and the mutagenic effects were studied in bone marrow, liver
nd large intestine. Further, free EMS  was determined in the circu-
ation and globin adducts in blood were determined in both studies.
omplete dose–response data were obtained for the gene mutation
tudy. As the studies were designed to determine a no-effect level of
xposure and to investigate the hypothesis that there was a thresh-
ld for mutation induction, it was of utmost importance to test the
ffect of various dose levels below the putative threshold for muta-
ions. When analyzing the data on micronucleus induction in the
one marrow of CD1 mice, lacZ mutation induction in the bone
arrow of MutaTMMouse mice, and, for both studies, the induc-
ion of globin adducts in peripheral blood, it became apparent that
ow-dose levels do not result in increases in these genotoxic effects
ut did substantially increase the adduct levels. Above the NOEL
oses of 25 mg/kg/day for lacZ induction and 80 mg/kg/day for MN
nduction, clear increases of the genotoxic effects were observed,
eaching a factor of 8.7- (MN) or 4.0-fold (lacZ) above control val-
es. Using the bilinear modeling software developed by Lutz and
utz [112], estimates of the breakpoint below which the slope of
he dose response curve did not differ from zero and conﬁdence
ntervals were determined and are shown in Table 2.
Regarding adduct levels in globin, it was evident that no thresh-
ld for adduct formation could be derived from the data. In fact,
n almost 10-fold increase over background was apparent already
t the lowest dose of about 1 mg/kg/day. At the no-effect doses for
enotoxicity, the ethylvaline levels surpassed the background val-
es by roughly a factor of 1000. In liver cells of animals treated at
he NOEL dose for lacZ mutation induction (50 mg/kg/day), it was
alculated that each daily EMS  dose induced 380,000 DNA alkyla-
ions without any measurable increase in mutation frequency. For
one marrow cells, the calculation yielded a total of 78,000 adducts
t the NOEL of 25 mg/kg/day, assuming a similar adduct induction
n bone marrow DNA as in liver DNA. The difference in calculated
dduct levels between the two organs might be due to the different
ell turnover (i.e., the liver cells have more time to repair adducts
efore replication).
These data, together with information on the type of DNA
dducts induced by EMS  and their removal, supported the hypoth-
sis of a threshold mechanism for mutation induction of EMS  with
 level below which DNA repair was assumed to prevent mutation
nduction. Ethylation by EMS  (and methylation by MMS)  occurs
redominantly at nitrogen sites (N7-G in DNA, cysteine nitrogens
nd terminal nitrogens in proteins), while oxygen sites within DNA
re targeted to a larger extent by ENU/MNU (O6-G, O2-T). For
emoval of the different DNA lesions, various repair mechanisms
re available.
These analyses were presented to the responsible regulatoryPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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uthority (EMA), which concurred that the data and analyses estab-
ished that the exposures experienced presented negligible risk to
he exposed patients. Therefore no cancer registry was  required
o be established and health follow-ups were not required. Thus, 56.7–118.2
 21.5–45.7
this case demonstrates that a quantitative risk analysis with good
experimental data combined with mechanistic and exposure infor-
mation can allow the conclusion of negligible risk at a calculated
margin below the derived PoDs, and that the concurrence of the
responsible regulatory authorities can be successfully achieved.
This example also illustrates the value of good exposure and PK
information combined with a mechanistic understanding of cel-
lular protective mechanisms that allows uncertainty factors to be
minimized.
More recently, Cao et al. [113] have conducted experiments in
which male gpt-delta transgenic mice were treated daily for 28 days
with 5–100 mg/kg EMS, and measurements were made on: (i) gpt
mutant frequencies in liver, lung, bone marrow, kidney, small intes-
tine, and spleen; and (ii) Pig-a mutant frequencies in peripheral
blood reticulocytes (RETs) and total red blood cells. MN induction
also was measured in peripheral blood RETs. These data were used
to calculate Points of Departure (PoDs) for the dose responses, i.e.,
no-observed-genotoxic-effect-levels (NOGELs), lower conﬁdence
limits of threshold effect levels (Td-LCIs), and lower conﬁdence lim-
its of 10% benchmark response rates (BMDL10). Similar PoDs were
calculated from the published EMS  dose–responses for LacZ muta-
tion and CD1 MN induction. Vehicle control gpt and Pig-a MFs  were
13–40-fold lower than published vehicle control LacZ MFs. In gen-
eral, the EMS  genotoxicity dose–responses in gpt-delta mice had
lower PoDs than those calculated from the MutaTMMouse and CD1
mouse data.
The results indicated that the magnitude and possibly the shape
of mutagenicity dose responses can differ among in vivo mod-
els, with lower PoDs generally detected by gene mutation assays
with lower backgrounds. Thus, the data published by Cao indi-
cate a lower observed effect level in gpt-delta mice than observed
in lacZ mice. While the lacZ data indicate a NOGEL of approxi-
mately 25 mg/kg/day, the NOGELs for the gpt-delta model seem to
lie below 13 mg/kg/day with a lowest effect level found in the lung
at 5 mg/kg/day. Thus, while the damage-speciﬁc DNA repair path-
ways for EMS  support in principle a sub-linear dose–response for
mutations induced by EMS, it appears to be advantageous to study
mutations in a model with a low spontaneous background versus a
higher background when determining low dose risk and NOGELs.
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